Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond

Overview

Journal Cancer Treat Res

Publisher Springer

Specialties Oncology
Pharmacology

Date 2018 Sep 1

PMID 30168118

Citations 12

Authors

Daniel Zainfeld

Amir Goldkorn

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is a common malignancy impacting countless men without curative options in the advanced state. Numerous therapies have been introduced in recent years improving survival and symptom control, yet optimal methods for predicting or monitoring response have not been developed. In the era of precision medicine, characterization of individual cancers is necessary to inform treatment decisions. Liquid biopsies, through evaluation of various blood-based analytes, provide a method of patient evaluation with potential applications in virtually all disease states. In this review, we will describe current approaches with a particular focus on demonstrated clinical utility in the evaluation and management of prostate cancer.

Citing Articles

Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers.

Chrenkova E, Studentova H, Hola K, Kahounova Z, Hendrychova R, Soucek K Front Oncol. 2024; 14:1394292.

PMID: 39319053 PMC: 11420116. DOI: 10.3389/fonc.2024.1394292.

Recent advances and future perspectives in the therapeutics of prostate cancer.

Varaprasad G, Gupta V, Prasad K, Kim E, Tej M, Mohanty P Exp Hematol Oncol. 2023; 12(1):80.

PMID: 37740236 PMC: 10517568. DOI: 10.1186/s40164-023-00444-9.

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy.

Palicelli A, Bonacini M, Croci S, Bisagni A, Zanetti E, de Biase D J Pers Med. 2021; 11(12).

PMID: 34945784 PMC: 8709072. DOI: 10.3390/jpm11121312.

Molecular Characterization of Prostate Cancers in the Precision Medicine Era.

Giunta E, Annaratone L, Bollito E, Porpiglia F, Cereda M, Banna G Cancers (Basel). 2021; 13(19).

PMID: 34638258 PMC: 8507555. DOI: 10.3390/cancers13194771.

Long Noncoding RNA NEAT1 as a Potential Candidate Biomarker for Prostate Cancer.

Nitusca D, Marcu A, Dema A, Balacescu L, Balacescu O, Bardan R Life (Basel). 2021; 11(4).

PMID: 33917553 PMC: 8067529. DOI: 10.3390/life11040320.

References

Liu X, Ledet E, Li D, Dotiwala A, Steinberger A, Feibus A . A Whole Blood Assay for AR-V7 and AR in Patients with Prostate Cancer. J Urol. 2016; 196(6):1758-1763. PMC: 5161406. DOI: 10.1016/j.juro.2016.06.095. View

Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

Hayes D, Cristofanilli M, Budd G, Ellis M, Stopeck A, Miller M . Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12(14 Pt 1):4218-24. DOI: 10.1158/1078-0432.CCR-05-2821. View

Paget S . The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989; 8(2):98-101. View

Tug S, Helmig S, Deichmann E, Schmeier-Jurchott A, Wagner E, Zimmermann T . Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. Exerc Immunol Rev. 2015; 21:164-73. View

Kidess E, Jeffrey S . Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?. Genome Med. 2013; 5(8):70. PMC: 3979136. DOI: 10.1186/gm474. View

Dijkstra S, Birker I, Smit F, Leyten G, de Reijke T, van Oort I . Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol. 2013; 191(4):1132-8. DOI: 10.1016/j.juro.2013.11.001. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Campton D, Ramirez A, Nordberg J, Drovetto N, Clein A, Varshavskaya P . High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer. 2015; 15:360. PMC: 4430903. DOI: 10.1186/s12885-015-1383-x. View

10.

Mikolajczyk S, Millar L, Tsinberg P, Coutts S, Zomorrodi M, Pham T . Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood. J Oncol. 2011; 2011:252361. PMC: 3090615. DOI: 10.1155/2011/252361. View

11.

McKiernan J, Donovan M, ONeill V, Bentink S, Noerholm M, Belzer S . A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2016; 2(7):882-9. DOI: 10.1001/jamaoncol.2016.0097. View

12.

Dawson S, Tsui D, Murtaza M, Biggs H, Rueda O, Chin S . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. DOI: 10.1056/NEJMoa1213261. View

13.

Ring A, Mineyev N, Zhu W, Park E, Lomas C, Punj V . EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low. Oncotarget. 2015; 6(42):44623-34. PMC: 4792580. DOI: 10.18632/oncotarget.5977. View

14.

Ignatiadis M, Dawson S . Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?. Ann Oncol. 2014; 25(12):2304-2313. DOI: 10.1093/annonc/mdu480. View

15.

Corcoran C, Rani S, ODriscoll L . miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate. 2014; 74(13):1320-34. DOI: 10.1002/pros.22848. View

16.

Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z . Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep. 2015; 5:7654. PMC: 4288210. DOI: 10.1038/srep07654. View

17.

Malapelle U, Sirera R, Jantus-Lewintre E, Reclusa P, Calabuig-Farinas S, Blasco A . Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn. 2017; 17(3):209-215. DOI: 10.1080/14737159.2017.1288568. View

18.

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

19.

Jiang R, Lu Y, Ho H, Li B, Chen J, Lin M . A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. Oncotarget. 2015; 6(42):44781-93. PMC: 4792591. DOI: 10.18632/oncotarget.6330. View

20.

Gupta V, Jafferji I, Garza M, Melnikova V, Hasegawa D, Pethig R . ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics. 2013; 6(2):24133. PMC: 3396706. DOI: 10.1063/1.4731647. View